Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
It has been shown in rodent models that chronic substance abuse is associated with a
rigidification of cell membrane fluidity due to a change in the membrane
cholesterol/phospholipids ratio. Upon substance withdrawal the membrane undergoes
reequilibration of this ratio, a process resulting both in an acute and a prolonged severe
withdrawal syndrome. MBM has developed a patented,phosphatidic acid-enriched phospholipid
platform ("LIBERTAL"), which is supposed to facilitate the membrane fluidity recovery. The
company has focused on nicotine withdrawal in smoking cessation,as primary target.